Xebio Co., Ltd. reported consolidated and non-earnings results for the six months ended September 30, 2014. For the six months, on consolidated basis, reported net sales of JPY 103,259 million compared to JPY 98,325 million a year ago. Operating profit was JPY 4,222 million compared to JPY 5,967 million a year ago. Ordinary profit was JPY 4,416 million compared to JPY 6,180 million a year ago. Net profit was JPY 2,349 million compared to JPY 3,188 million a year ago. Capital expenditure was JPY 4,333 million.

For the six months, on non-consolidated basis, reported net sales of JPY 69,096 million compared to JPY 70,432 million a year ago. Operating profit was JPY 3,589 million compared to JPY 5,743 million a year ago. Ordinary profit was JPY 3,873 million compared to JPY 6,111 million a year ago. Net profit was JPY 2,125 million compared to JPY 3,674 million a year ago. Capital expenditure was JPY 3,829 million.

For the second quarter, on consolidated basis, the company reported net sales of JPY 50,318 million compared to JPY 52,941 million in the last quarter. Operating profit was JPY 857 million compared to JPY 3,364 million in the last quarter. Ordinary profit was JPY 899 million compared to JPY 3,516 million in the last quarter. Net profit was JPY 323 million compared to JPY 2,026 million in the last quarter. Capital expenditure was JPY 9,339 million compared to JPY 9,211 million a year ago.

The company provided earnings consolidated and non-consolidated guidance for the year ending March 31, 2015. For the year, on consolidated basis, the company expects net sales of JPY 220,072 million, operating profit of JPY 10,048 million, ordinary profit of JPY 10,452 million and net profit of JPY 5,481 million.

For the year, on non-consolidated basis, the company expects net sales of JPY 145,644 million, operating profit of JPY 8,202 million, ordinary profit of JPY 8,771 million and net profit of JPY 5,217 million.